2023
Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project
Rogal S, Taddei T, Monto A, Yakovchenko V, Patton H, Merante M, Spoutz P, Chia L, Yudkevich J, Aytaman A, Rabiee A, John B, Blechacz B, Cai C, Gilles H, Shah A, McCurdy H, Puri P, Jou J, Mazhar K, Dominitz J, Anwar J, Morgan T, Ioannou G. Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project. Clinical Gastroenterology And Hepatology 2023, 22: 324-338. PMID: 37460005, PMCID: PMC10788380, DOI: 10.1016/j.cgh.2023.07.002.Peer-Reviewed Original ResearchGood performance statusCurative treatmentHCC screeningHCC diagnosisPerformance statusEarly-stage diagnosisMedical record extractionAdvanced liver diseaseReceipt of treatmentStage diagnosisPreventative health care servicesHepatocellular carcinoma stageVA primary careQuality improvement projectHealth care servicesHepatocellular carcinoma diagnosisElectronic health recordsCirrhosis careNoncurative treatmentLiver diseaseCancer screeningPrimary careMultivariable modelCarcinoma stageNew diagnosis
2022
Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic
Serper M, Tapper EB, Kaplan DE, Taddei TH, Mahmud N. Patterns of Care Utilization and Hepatocellular Carcinoma Surveillance: Tracking Care Across the Pandemic. The American Journal Of Gastroenterology 2022, 118: 294-303. PMID: 36114778, PMCID: PMC9898115, DOI: 10.14309/ajg.0000000000002011.Peer-Reviewed Original ResearchConceptsOutpatient primary care providerHepatocellular carcinoma surveillancePrimary care providersHCC surveillanceCare providersHCC surveillance ratesGastroenterology/hepatologyFacility-level variablesCirrhosis cohortPatient demographicsClinical factorsTotal cohortCare utilizationNational cohortOutpatient utilizationSpecialty careInpatient careMultivariable modelPercentage of timePopulation-based approachSurveillance ratesAppointment ratesAdjusted modelVisit ratesCoronavirus disease
2020
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study
Hajiev S, Allara E, Motedayеn Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R. Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. British Journal Of Cancer 2020, 124: 407-413. PMID: 33071284, PMCID: PMC7852559, DOI: 10.1038/s41416-020-01116-9.Peer-Reviewed Original ResearchConceptsOverall survivalHepatocellular carcinomaCohort studySorafenib-related toxicityInternational cohort studyMedian overall survivalMulticentre cohort studyLow-dose therapyCommon prognostic factorsSimilar overall incidenceDoses of sorafenibImpact of ageConclusionsClinical outcomesSorafenib 800Sorafenib dosingElderly patientsOlder patientsPrognostic factorsOverall incidenceClinical efficacyLiver functionLarge tumorsMultivariable modelGrade 2PatientsSurvival Benefit of Liver Transplantation for Hepatocellular Carcinoma.
Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020, 104: 104-112. PMID: 31283688, PMCID: PMC6928443, DOI: 10.1097/tp.0000000000002816.Peer-Reviewed Original ResearchConceptsIncremental survival benefitLiver transplantSurvival benefitHepatocellular carcinomaEnd-stage liver disease (MELD) scoreOverall long-term survivalIntermediate-stage hepatocellular carcinomaLiver Disease scoreRetrospective cohort studyStage hepatocellular carcinomaHazard of deathVeterans Health AdministrationImmortal time biasLong-term survivalUnderwent resectionLiver transplantationAnalytic cohortCohort studyCurative optionMultivariable modelHCC diagnosisDisease scoreResectionPatientsHealth Administration
2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
2018
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis